The company will use proceeds from the Series B round to continue advancing its chimeric antigen receptor
(CAR) and T-cell receptor (TCR) pipeline, including CAR T-cell therapies directed against CD19 currently in phase 1/2 trials and solid tumor targets.
Several studies presented during the meeting detail results using one method known as chimeric antigen receptor
(CAR) cell engineering.
Clinical evidence has demonstrated that a patients' peripheral blood T cells, which have been engineered with T cell receptor (TCRs) and chimeric antigen receptors
(CARs) that recognize tumor specific molecules, can traffic directly to the tumor, become activated upon engagement with the tumor antigen, and selectively eradicate tumors.
Kite), a clinical stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced the appointment of three leading experts in the areas of immunotherapy, chimeric antigen receptor
(CAR) technology, and gene therapy to its Scientific Advisory Board (SAB).
The agreement includes rights to use Life Technologies' intellectual property to perform the resulting therapy, and is exclusive for use in the field of chimeric antigen receptors
for the treatment of cancer.
TNK(TM) (Chimeric Antigen Receptor
Tumor-attacking Neukoplast) immunotherapies for the treatment of cancer and infectious diseases.
There are a few types of cellular immunotherapies including: tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells bearing chimeric antigen receptors
(CARs), and recombinant TCR technology.
The future is now: Chimeric antigen receptors
as new targeted therapies for childhood cancer.
The large number of V, D, J, and C segments results in many combinations, which can be transcribed and translated to millions of different antigen receptors
This occurs because the AnergiX complex binds to autoimmune T cell antigen receptors
in the absence of co-stimulatory signals normally provided by antigen presenting cells.
Over the past two decades, scientists pursuing cell therapy, one branch of the burgeoning field of cancer immunotherapy, have been refining cell-surface sensors known as chimeric antigen receptors
, or CARs.
Its focus is on pioneering disruptive technologies ranging from individualized mRNA based medicines through highly innovative Chimeric Antigen Receptors
/T-cell Receptor-based products and antibody checkpoint immunomodulators.
Nasdaq: PRCT) announced today that its five-year agreement with Bristol-Myers Squibb to collaborate on the development of T cell antigen receptors
for autoimmune diseases will end, as scheduled, in February 1995.
The deal will see the partners giving $100 million to MD Anderson for a CAR-T technology, made through a process in which researchers remove T cells from a patient's blood and provide them with targeting mechanisms called chimeric antigen receptors
(CARs), which seek out and bind to proteins that cancer cells express.
Andre Choulika, Chairman and Chief Executive Officer of Cellectis stated: We are very pleased to enter into these agreements that strengthen Cellectis position in the uses of TALEN gene editing in Cellectis core businesses, and solidifies our position as a leader in the field of engineered CART Chimeric Antigen Receptors